Results · Apr-Jun 2026 · filed 4 Aug 2026
Alembic Pharmaceuticals Q1 FY27 results
Sales grew 26% to ₹2,150 crore from ₹1,711 crore in Apr-Jun 2025.
Operating profit grew 18% to ₹332 crore, an operating margin of 15.4% (down 1.0 points from a year ago).
Net profit grew 12% to ₹172 crore from ₹154 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +16%, net profit −14%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 2,150 | 1,711 | +26% |
| Operating profit (EBITDA) | 331.9 | 281.3 | +18% |
| Operating margin | 15.4% | 16.4% | −1.0 pts |
| Net profit | 172.4 | 153.6 | +12% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The earnings call
Apr–Jun 2026 revenue grew 26% to ₹2,150 crore with broad-based growth across India Branded (7%), International Generics (37%) & API (33%). Management raised FY27 growth guidance to mid-teen range from low double-digit, driven by US Generics momentum.
The last 7 quarters
Filings that week
- 10 Aug 2026Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
- 10 Aug 2026Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- 6 Aug 2026Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- 5 Aug 2026Shareholder Meeting / Postal Ballot-Outcome of AGM
- 5 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 4 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 4 Aug 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
- 4 Aug 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.